Drug intelligence / Profile preview

APG-157

Development stage: Phase 3
Lead developer: Aveta Biomics
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

APG-157 is Aveta Biomics' investigational oral botanical immunomodulatory anticancer drug. It is a proprietary multi-polyphenol formulation containing curcumin and is administered as a dissolving hydrogel pastille or soft lozenge. APG-157 is designed to reprogram the tumor microenvironment by reducing tumor-promoting inflammatory and immunosuppressive signaling, promoting macrophage polarization toward an M1-like antitumor state, and supporting intratumoral cytotoxic T-cell and natural-killer-cell activity. Its molecular binding targets and complete proprietary constituent composition have not been publicly established. Development includes a global Phase 3 study in locally advanced head and neck squamous cell carcinoma, Phase 2 oral-dysplasia development, and Phase 1b/2a development with bevacizumab in recurrent high-grade glioma. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/curcumin-polyphenols-containing-botanical-agent-apg-157))

Other names: APG 157APG157APG-157curcumin/polyphenols-containing botanical agent APG-157

Targets

IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on APG-157.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG-157.

Explore the full profile